These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 9051086)

  • 1. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis.
    Cazzola M; Borgna-Pignatti C; Locatelli F; Ponchio L; Beguin Y; De Stefano P
    Transfusion; 1997 Feb; 37(2):135-40. PubMed ID: 9051086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major.
    Cazzola M; De Stefano P; Ponchio L; Locatelli F; Beguin Y; Dessi C; Barella S; Cao A; Galanello R
    Br J Haematol; 1995 Mar; 89(3):473-8. PubMed ID: 7734344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
    Pasricha SR; Frazer DM; Bowden DK; Anderson GJ
    Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
    Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum transferrin receptor as a marker of erythropoiesis suppression in patients on chronic transfusion.
    Tancabelic J; Sheth S; Paik M; Piomelli S
    Am J Hematol; 1999 Feb; 60(2):121-5. PubMed ID: 9929103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients.
    Angelucci E; Muretto P; Lucarelli G; Ripalti M; Baronciani D; Erer B; Galimberti M; Giardini C; Gaziev D; Polchi P
    Blood; 1997 Aug; 90(3):994-8. PubMed ID: 9242528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major.
    Mirlohi MS; Yaghooti H; Shirali S; Aminasnafi A; Olapour S
    Ann Hematol; 2018 Apr; 97(4):679-684. PubMed ID: 29318368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron status and oxidative stress in beta-thalassemia patients in Jakarta.
    Laksmitawati DR; Handayani S; Udyaningsih-Freisleben SK; Kurniati V; Adhiyanto C; Hidayat J; Kusnandar S; Dillon HS; Munthe BG; Wirawan R; Soegianto RR; Ramelan W; Freisleben HJ
    Biofactors; 2003; 19(1-2):53-62. PubMed ID: 14757977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythroid bone marrow activity and red cell hemoglobinization in iron sufficient beta-thalassemia heterozygotes as reflected by soluble transferrin receptor and reticulocyte hemoglobin in content. Correlation with genotypes and Hb A(2) levels.
    Skarmoutsou C; Papassotiriou I; Traeger-Synodinos J; Stamou H; Ladis V; Metaxotou-Mavrommati A; Stamoulakatou A; Kanavakis E
    Haematologica; 2003 Jun; 88(6):631-6. PubMed ID: 12801838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD; Motta I
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
    Albo C; Cabrera J; Dios A; Castro M; Ares C; Constenla I; López D
    Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.
    Chaidos A; Makis A; Hatzimichael E; Tsiara S; Gouva M; Tzouvara E; Bourantas KL
    Acta Haematol; 2004; 111(4):189-95. PubMed ID: 15153710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
    Ehlers KH; Giardina PJ; Lesser ML; Engle MA; Hilgartner MW
    J Pediatr; 1991 Apr; 118(4 Pt 1):540-5. PubMed ID: 2007928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High transfusion in children with beta-thalassemia/Hb E: clinical and laboratory assessment of 18 cases.
    Torcharus K; Withayathawornwong W; Sriphaisal T; Krutvacho T; Arnutti P; Suwanasophorn C
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():96-9. PubMed ID: 7886617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia.
    Ricchi P; Meloni A; Costantini S; Spasiano A; Di Matola T; Pepe A; Cinque P; Filosa A
    Ann Hematol; 2017 Sep; 96(9):1541-1546. PubMed ID: 28707012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary Functions in Children With Thalassemia Major.
    Ozyoruk D; Misirlioglu ED
    J Pediatr Hematol Oncol; 2015 Nov; 37(8):605-10. PubMed ID: 26422288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeuetic management of patients with thalassemia major].
    Thuret I
    Bull Soc Pathol Exot; 2001 May; 94(2):95-7. PubMed ID: 11475036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood transfusion therapy for β-thalassemia major and hemoglobin E β-thalassemia: Adequacy, trends, and determinants in Sri Lanka.
    Mettananda S; Pathiraja H; Peiris R; Wickramarathne N; Bandara D; de Silva U; Mettananda C; Premawardhena A
    Pediatr Blood Cancer; 2019 May; 66(5):e27643. PubMed ID: 30697927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.
    Artuso I; Lidonnici MR; Altamura S; Mandelli G; Pettinato M; Muckenthaler MU; Silvestri L; Ferrari G; Camaschella C; Nai A
    Blood; 2018 Nov; 132(21):2286-2297. PubMed ID: 30209118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.